作者:Babasaheb P. Bandgar、Rajendra Janardan Sarangdhar、Santosh Viswakarma、Fakrudeen Ali Ahamed
DOI:10.1021/jm101085j
日期:2011.3.10
Synthesis and biological evaluation of orally active prodrugs (1a−d) of indomethacin are described. Prodrugs 1a−c showed a similar degree of anti-inflammatory activity, and prodrug 1d was found to be less potent than the parent drug indomethacin (1). Ulcer index (UI) data indicated that 1a (UI = 19), 1c (UI = 0), and 1d (UI = 0) were substantially less ulcerogenic and 1b (UI = 62) was more ulcerogenic
描述了吲哚美辛的口服活性前药(1a - d)的合成和生物学评估。前药1a - c表现出相似的抗炎活性,并且发现前药1d的效力比母体药物吲哚美辛(1)低。溃疡指数(UI)数据表明,1A(UI = 19),1C(UI = 0),和1D(UI = 0)为显着更少的致溃疡和1b中(UI = 62)比母体药物更溃疡1(UI = 47)。这些前药在酸性和碱性pH下显示出良好的稳定性,并且比母体药物化合物更具亲脂性1,由辛醇-缓冲液系统在pH 7.4和3.0下测得的分配系数表示。在体内研究的基础上,选择了1a和1c化合物用于大鼠肝微粒体(RLM)和大鼠血浆(RP)的代谢稳定性,并且发现它们在酶学上均不稳定。前药1a和1c作为有效的抗炎药出现,与母体药物消炎痛相比,溃疡的可能性较小。